

Guard Therapeutics recruits new Head of CMC

Guard Therapeutics announces that the company has appointed Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls). Torbjörn Larsson will join the management team and will report directly to the CEO.

Torbjörn Larsson has over 30 years of experience in the life science industry, including from roles as Director Pharmaceutical R&D at Medivir, Director of CMC at OxyPharma, and several positions within Pharmacia and Kabi. Torbjörn studied chemistry and biotechnology at Uppsala University and comes most recently from Aprea Therapeutics as Director Commercial Production in the CMC area. Torbjörn Larsson will take up the position on 1 May and succeed Lars Olsson, who will continue to assist the company with his expertise for some time to come.

"With his broad experience, Torbjörn Larsson brings great value to the company in the continued development of our drug candidate ROSgard, which is now being evaluated in an ongoing clinical phase 2 study," says Guard Therapeutics CEO, Tobias Agervald.

The investigational drug ROSgard has the ability to counteract severe oxidative stress – a common denominator for many different types of acute kidney damage. Guard Therapeutics has chosen to prioritize treatment in connection with open heart surgery and use of a heart-lung machine in the initial clinical development phase.

For further information, please contact:

Tobias Agervald, CEO

Telephone: +46 8 670 65 51

E-mail: info@guardtherapeutics.com

About Guard Therapeutics

Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company's clinical investigational drug ROSgard is being developed as a protective treatment against acute kidney injury with an initial focus on patients undergoing heart surgery. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.

Attachments

[Guard Therapeutics recruits new Head of CMC](#)